Xin Xi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xin Xi has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Guili Huang
Department of Pharmacy The Third Affiliated Hospital of Chongqing Medical University Chongqing China
3 shared publicationsHaowen Tan
Department of Pharmacy Wuzhou Red Cross Hospital Wuzhou China
3 shared publicationsLuping Luo
Department of Pharmacy Wuzhou Red Cross Hospital Wuzhou China
3 shared publicationsWeiwei Lan
Department of Pharmacy Wuzhou Red Cross Hospital Wuzhou China
3 shared publicationsWenjun Li
Department of Pharmacy The Third Affiliated Hospital of Chongqing Medical University Chongqing China
3 shared publicationsYing Chen
Office of Good Clinical Practice Wuzhou Red Cross Hospital Wuzhou China
3 shared publications
Latest Publications
- 11 February 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (7) , 10861-10871
Medication association analysis of antimicrobial-induced arrhythmias based on FP-growth frequent pattern mining
Antibiotic-related arrhythmias represent a major clinical challenge, characterized by risk patterns that remain not fully elucidated. This study employed the FP-growth algorithm to uncover associations between antibiotic classes and specific arrhythmias, and to identify key high-risk patient profiles. We included 246 cases of antibiotic-related arrhythmia from Center for Adverse Drug Reaction Monitoring of Chongqing (2013–2023). In the FP-growth association algorithm, we took antibiotic categories, age, gender, and time to arrhythmia onset as the antecedents, and the types of arrhythmias as the consequents. The minimum thresholds were set at a support of ≥ 1.0%, a confidence of ≥ 50.0%, and a lift of > 1.8. Sinus tachycardia (36.18%), premature contractions (25.20%), and QT prolongation (16.26%) were the predominant arrhythmias. Key associations included antituberculosis drugs and quinolones with QT prolongation (lift 3.514—6.150 and 3.075—4.100, respectively), and macrolides with premature beats (lift 2.645—2.976). Crucially, onset timing differed: QT prolongation occurred mainly after 5 days of anti-tuberculosis therapy or with prolonged quinolone use, whereas premature contractions and sinus tachycardia predominantly emerged during drug infusion. Moreover, females were more prone to QT prolongation induced by anti-tuberculosis drugs and premature contractions associated with macrolides, whereas males exhibited a stronger link to quinolones. Furthermore, the association with sinus tachycardia was more pronounced in children than in adults. In conclusion, The FP-growth algorithm effectively uncovered complex antibiotic-arrhythmia risk patterns. While controlling for other susceptible factors (including underlying disease, concomitant medication, and electrolyte disorders), these findings highlight distinct patterns of association that may inform more targeted monitoring during antibiotic therapy, particularly regarding the timing and type of arrhythmic events.
- 11 February 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (7) , 10861-10871
Medication association analysis of antimicrobial-induced arrhythmias based on FP-growth frequent pattern mining
Antibiotic-related arrhythmias represent a major clinical challenge, characterized by risk patterns that remain not fully elucidated. This study employed the FP-growth algorithm to uncover associations between antibiotic classes and specific arrhythmias, and to identify key high-risk patient profiles. We included 246 cases of antibiotic-related arrhythmia from Center for Adverse Drug Reaction Monitoring of Chongqing (2013–2023). In the FP-growth association algorithm, we took antibiotic categories, age, gender, and time to arrhythmia onset as the antecedents, and the types of arrhythmias as the consequents. The minimum thresholds were set at a support of ≥ 1.0%, a confidence of ≥ 50.0%, and a lift of > 1.8. Sinus tachycardia (36.18%), premature contractions (25.20%), and QT prolongation (16.26%) were the predominant arrhythmias. Key associations included antituberculosis drugs and quinolones with QT prolongation (lift 3.514—6.150 and 3.075—4.100, respectively), and macrolides with premature beats (lift 2.645—2.976). Crucially, onset timing differed: QT prolongation occurred mainly after 5 days of anti-tuberculosis therapy or with prolonged quinolone use, whereas premature contractions and sinus tachycardia predominantly emerged during drug infusion. Moreover, females were more prone to QT prolongation induced by anti-tuberculosis drugs and premature contractions associated with macrolides, whereas males exhibited a stronger link to quinolones. Furthermore, the association with sinus tachycardia was more pronounced in children than in adults. In conclusion, The FP-growth algorithm effectively uncovered complex antibiotic-arrhythmia risk patterns. While controlling for other susceptible factors (including underlying disease, concomitant medication, and electrolyte disorders), these findings highlight distinct patterns of association that may inform more targeted monitoring during antibiotic therapy, particularly regarding the timing and type of arrhythmic events.
A pharmacovigilance study of drug‐reduced male semen quality based on the Food and Drug Administration adverse event reporting system database
Background: Real‐world big data studies on drug‐reduced male semen quality are few and far between, with most studies based on animal trials, small scale retrospective studies, or a limited number of pre‐market clinical trials.Methods: This study aimed to identify culprit drugs that reduced male semen quality based on the United States Food and Drug Administration adverse event reporting system. The Medical Dictionary for Regulatory Activities preferred terms and standardized Medical Dictionary for Regulatory Activities queries were used to define reduced male semen quality. Adverse events related to drug‐reduced male semen quality were then analyzed by disproportionality analysis using the United States Food and Drug Administration adverse event reporting system data between 2004 and 2023.Results: At the preferred term level, 59 drugs with risk signals were detected to be associated with drug‐reduced male semen quality, with the three most frequently reported second‐level Anatomical Therapeutic Chemical groups being antineoplastic agents (n = 16, 27.12%), psychoanaleptics (n = 9, 15.25%), and psycholeptics (n = 6, 10.17%). At the standardized Medical Dictionary for Regulatory Activities queries level, the five drugs with the greatest number of cases were finasteride (845 cases, IC025 = 7.72), dutasteride (163 cases, IC025 = 7.22), tamsulosin (148 cases, IC025 = 5.99), testosterone (101 cases, IC025 = 4.08), and valproic acid (54 cases, IC025 = 2.44). Additionally, clinical information about drug‐reduced male semen quality is absent from the Summary of Product Characteristics of 41 drugs in our study.Conclusions: Using the United States Food and Drug Administration adverse event reporting system database, we offer a list of drugs with risk signals for reducing male semen quality. In the future, there is still a need for more studies on drugs whose effects on male semen quality are not fully understood.
A pharmacovigilance study of drug‐reduced male semen quality based on the Food and Drug Administration adverse event reporting system database
Background: Real‐world big data studies on drug‐reduced male semen quality are few and far between, with most studies based on animal trials, small scale retrospective studies, or a limited number of pre‐market clinical trials.Methods: This study aimed to identify culprit drugs that reduced male semen quality based on the United States Food and Drug Administration adverse event reporting system. The Medical Dictionary for Regulatory Activities preferred terms and standardized Medical Dictionary for Regulatory Activities queries were used to define reduced male semen quality. Adverse events related to drug‐reduced male semen quality were then analyzed by disproportionality analysis using the United States Food and Drug Administration adverse event reporting system data between 2004 and 2023.Results: At the preferred term level, 59 drugs with risk signals were detected to be associated with drug‐reduced male semen quality, with the three most frequently reported second‐level Anatomical Therapeutic Chemical groups being antineoplastic agents (n = 16, 27.12%), psychoanaleptics (n = 9, 15.25%), and psycholeptics (n = 6, 10.17%). At the standardized Medical Dictionary for Regulatory Activities queries level, the five drugs with the greatest number of cases were finasteride (845 cases, IC025 = 7.72), dutasteride (163 cases, IC025 = 7.22), tamsulosin (148 cases, IC025 = 5.99), testosterone (101 cases, IC025 = 4.08), and valproic acid (54 cases, IC025 = 2.44). Additionally, clinical information about drug‐reduced male semen quality is absent from the Summary of Product Characteristics of 41 drugs in our study.Conclusions: Using the United States Food and Drug Administration adverse event reporting system database, we offer a list of drugs with risk signals for reducing male semen quality. In the future, there is still a need for more studies on drugs whose effects on male semen quality are not fully understood.
- Open Access
- 13 May 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1363382
A real-world pharmacovigilance study of drug-induced QT interval prolongation: analysis of spontaneous reports submitted to FAERS
Purpose: To identify the most commonly reported drugs associated with QT interval prolongation in the FDA Adverse Event Reporting System (FAERS) and evaluate their risk for QT interval prolongation.Methods: We employed the preferred term (PT) “electrocardiogram QT prolonged” from the Medical Dictionary for Regulatory Activities (MedDRA) 26.0 to identify adverse drug events (ADEs) of QT interval prolongation in the FAERS database from the period 2004–2022. Reporting odds ratio (ROR) was performed to quantify the signals of ADEs.Results: We listed the top 40 drugs that caused QT interval prolongation. Among them, the 3 drugs with the highest number of cases were quetiapine (1,151 cases, ROR = 7.62), olanzapine (754 cases, ROR = 7.92), and citalopram (720 cases, ROR = 13.63). The two most frequently reported first-level Anatomical Therapeutic Chemical (ATC) groups were the drugs for the nervous system (n = 19, 47.50%) and antiinfectives for systemic use (n = 7, 17.50%). Patients with missing gender (n = 3,482, 23.68%) aside, there were more females (7,536, 51.24%) than males (5,158, 35.07%) were involved. 3,720 patients (25.29%) suffered serious clinical outcomes resulting in deaths or life-threatening conditions. Overall, most drugs that caused QT interval prolongation had early failure types according to the assessment of the Weibull's shape parameter (WSP) analysis.Conclusions: Our study offered a list of drugs that frequently caused QT interval prolongation based on the FAERS system, along with a description of some risk profiles for QT interval prolongation brought on by these drugs. When prescribing these drugs in clinical practice, we should closely monitor the occurrence of ADE for QT interval prolongation.
- 13 May 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1363382
Open AccessA real-world pharmacovigilance study of drug-induced QT interval prolongation: analysis of spontaneous reports submitted to FAERS
Purpose: To identify the most commonly reported drugs associated with QT interval prolongation in the FDA Adverse Event Reporting System (FAERS) and evaluate their risk for QT interval prolongation.Methods: We employed the preferred term (PT) “electrocardiogram QT prolonged” from the Medical Dictionary for Regulatory Activities (MedDRA) 26.0 to identify adverse drug events (ADEs) of QT interval prolongation in the FAERS database from the period 2004–2022. Reporting odds ratio (ROR) was performed to quantify the signals of ADEs.Results: We listed the top 40 drugs that caused QT interval prolongation. Among them, the 3 drugs with the highest number of cases were quetiapine (1,151 cases, ROR = 7.62), olanzapine (754 cases, ROR = 7.92), and citalopram (720 cases, ROR = 13.63). The two most frequently reported first-level Anatomical Therapeutic Chemical (ATC) groups were the drugs for the nervous system (n = 19, 47.50%) and antiinfectives for systemic use (n = 7, 17.50%). Patients with missing gender (n = 3,482, 23.68%) aside, there were more females (7,536, 51.24%) than males (5,158, 35.07%) were involved. 3,720 patients (25.29%) suffered serious clinical outcomes resulting in deaths or life-threatening conditions. Overall, most drugs that caused QT interval prolongation had early failure types according to the assessment of the Weibull's shape parameter (WSP) analysis.Conclusions: Our study offered a list of drugs that frequently caused QT interval prolongation based on the FAERS system, along with a description of some risk profiles for QT interval prolongation brought on by these drugs. When prescribing these drugs in clinical practice, we should closely monitor the occurrence of ADE for QT interval prolongation.
- Open Access
- 21 November 2023
- Published by Wiley
A real-world pharmacovigilance study of drug-induced QT interval prolongation:analysis of spontaneous reports submitted to FAERS
Objective: To identify the most commonly reported drugs associated with QT interval prolongation in the FDA Adverse Event Reporting System (FAERS) and evaluate their risk for QT interval prolongation. Methods: We employed the preferred term (PT) “electrocardiogram QT prolonged” from the Medical Dictionary for Regulatory Activities (MedDRA) 26.0 to identify adverse drug events (ADEs) of QT interval prolongation in the FAERS database from the period 2004-2022. Reporting odds ratio (ROR) was performed to quantify the signals of ADEs. Results: We listed the top 40 drugs that caused QT interval prolongation. The 3 drugs with the highest number of cases were quetiapine (1151 cases, ROR 7.62), olanzapine (754 cases, ROR 7.92), and citalopram (720 cases, ROR 13.63). The two most frequently reported first-level Anatomical Therapeutic Chemical (ATC) groups were the drugs for nervous system (n=19, 47.50%) and antiinfectives for systemic use (n=7, 17.50%). More females (7,536, 51.24%) than males (5,158, 35.07%) were involved. 3720 patients (25.29%) suffered serious clinical outcomes resulting in deaths or life-threatening conditions. Most drugs caused QT interval prolongation had early failure types according to the assessment of the Weibull’s shape parameter (WSP) analysis. Conclusions: Our study offered a list of drugs that frequently caused QT interval prolongation based on the FAERS system, along with a description of some risk profiles for QT interval prolongation brought on by these drugs. When prescribing these drugs in clinical practice, we should closely monitor the occurrence of ADE for QT interval prolongation. Keywords: QT interval prolongation, pharmacovigilance, FAERS, data mining
- 21 November 2023
- Published by Wiley
Open AccessA real-world pharmacovigilance study of drug-induced QT interval prolongation:analysis of spontaneous reports submitted to FAERS
Objective: To identify the most commonly reported drugs associated with QT interval prolongation in the FDA Adverse Event Reporting System (FAERS) and evaluate their risk for QT interval prolongation. Methods: We employed the preferred term (PT) “electrocardiogram QT prolonged” from the Medical Dictionary for Regulatory Activities (MedDRA) 26.0 to identify adverse drug events (ADEs) of QT interval prolongation in the FAERS database from the period 2004-2022. Reporting odds ratio (ROR) was performed to quantify the signals of ADEs. Results: We listed the top 40 drugs that caused QT interval prolongation. The 3 drugs with the highest number of cases were quetiapine (1151 cases, ROR 7.62), olanzapine (754 cases, ROR 7.92), and citalopram (720 cases, ROR 13.63). The two most frequently reported first-level Anatomical Therapeutic Chemical (ATC) groups were the drugs for nervous system (n=19, 47.50%) and antiinfectives for systemic use (n=7, 17.50%). More females (7,536, 51.24%) than males (5,158, 35.07%) were involved. 3720 patients (25.29%) suffered serious clinical outcomes resulting in deaths or life-threatening conditions. Most drugs caused QT interval prolongation had early failure types according to the assessment of the Weibull’s shape parameter (WSP) analysis. Conclusions: Our study offered a list of drugs that frequently caused QT interval prolongation based on the FAERS system, along with a description of some risk profiles for QT interval prolongation brought on by these drugs. When prescribing these drugs in clinical practice, we should closely monitor the occurrence of ADE for QT interval prolongation. Keywords: QT interval prolongation, pharmacovigilance, FAERS, data mining
- Open Access
- 27 June 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (7) , 1109
Real-World Data in Pharmacovigilance Database Provides a New Perspective for Understanding the Risk of Clostridium difficile Infection Associated with Antibacterial Drug Exposure
Antibacterial drug exposure (ADE) is a well-known potential risk factor for Clostridium difficile infection (CDI), but it remains controversial which certain antibacterial drugs are associated with the highest risk of CDI occurrence. To summarize CDI risk associated with ADE, we reviewed the CDI reports related to ADE in the FDA Adverse Event Reporting System database and conducted disproportionality analysis to detect adverse reaction (ADR) signals of CDI for antibacterial drugs. A total of 8063 CDI reports associated with ADE were identified, which involved 73 antibacterial drugs. Metronidazole was the drug with the greatest number of reports, followed by vancomycin, ciprofloxacin, clindamycin and amoxicillin. In disproportionality analysis, metronidazole had the highest positive ADR signal strength, followed by vancomycin, cefpodoxime, ertapenem and clindamycin. Among the 73 antibacterial drugs, 58 showed at least one positive ADR signal, and ceftriaxone was the drug with the highest total number of positive signals. Our study provided a real-world overview of CDI risk for AED from a pharmacovigilance perspective and showed risk characteristics for different antibacterial drugs by integrating its positive–negative signal distribution. Meanwhile, our study showed that the CDI risk of metronidazole and vancomycin may be underestimated, and it deserves further attention and investigation.
- 27 June 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (7) , 1109
Open AccessReal-World Data in Pharmacovigilance Database Provides a New Perspective for Understanding the Risk of Clostridium difficile Infection Associated with Antibacterial Drug Exposure
Antibacterial drug exposure (ADE) is a well-known potential risk factor for Clostridium difficile infection (CDI), but it remains controversial which certain antibacterial drugs are associated with the highest risk of CDI occurrence. To summarize CDI risk associated with ADE, we reviewed the CDI reports related to ADE in the FDA Adverse Event Reporting System database and conducted disproportionality analysis to detect adverse reaction (ADR) signals of CDI for antibacterial drugs. A total of 8063 CDI reports associated with ADE were identified, which involved 73 antibacterial drugs. Metronidazole was the drug with the greatest number of reports, followed by vancomycin, ciprofloxacin, clindamycin and amoxicillin. In disproportionality analysis, metronidazole had the highest positive ADR signal strength, followed by vancomycin, cefpodoxime, ertapenem and clindamycin. Among the 73 antibacterial drugs, 58 showed at least one positive ADR signal, and ceftriaxone was the drug with the highest total number of positive signals. Our study provided a real-world overview of CDI risk for AED from a pharmacovigilance perspective and showed risk characteristics for different antibacterial drugs by integrating its positive–negative signal distribution. Meanwhile, our study showed that the CDI risk of metronidazole and vancomycin may be underestimated, and it deserves further attention and investigation.